Letter: elevated HBV DNA predicts poor survival in hepatocellular carcinoma after hepatic resection
- PMID: 33333596
- DOI: 10.1111/apt.16132
Letter: elevated HBV DNA predicts poor survival in hepatocellular carcinoma after hepatic resection
Comment in
-
Letter: elevated HBV DNA predicts poor survival in hepatocellular carcinoma after hepatic resection-authors' reply.Aliment Pharmacol Ther. 2021 Jan;53(1):203-204. doi: 10.1111/apt.16162. Aliment Pharmacol Ther. 2021. PMID: 33333613 No abstract available.
Comment on
-
East Asia expert opinion on treatment initiation for chronic hepatitis B.Aliment Pharmacol Ther. 2020 Nov;52(10):1540-1550. doi: 10.1111/apt.16097. Epub 2020 Sep 20. Aliment Pharmacol Ther. 2020. PMID: 32951256 Review.
References
REFERENCES
-
- Kao JH, Hu TH, Jia J, et al. East Asia expert opinion on treatment initiation for chronic hepatitis B. Aliment Pharmacol Ther. 2020;52:1540-1550.
-
- European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67:370-398.
-
- Gane EJ, Charlton MR, Mohamed R, et al. Asian consensus recommendations on optimizing the diagnosis and initiation of treatment of hepatitis B virus infection in resource-limited settings. J Viral Hepat. 2020;27:466-475.
-
- Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67:1560-1599.
-
- Li ZC, Li Z, Li C, et al. Letter: elevated aspartate aminotransferase and aspartate aminotransferase to alanine aminotransferase ratio predicts poor survival in hepatocellular carcinoma after resection. Aliment Pharmacol Ther. 2020;52:1762-1763
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical